Pacemaker Device Testing Patent Snapshot 2026
The pacemaker device testing patent space is a small, highly concentrated corpus dominated by a handful of institutional and corporate filers, with University Health Network holding the leading position. Filing activity peaked in 2020 and has since eased back, placing the field in a decline stage on an annual-volume basis.
University Health Network leads a tightly held corpus
University Health Network ranks first among all filers, followed by Pacesetter Inc in second position. The top five filers account for 92% of the combined total of the ranked applicants visible in this query, signalling an unusually concentrated visible assignee structure.
The tier gap between the leader and the rest of the field is narrow in absolute terms but steep in proportional terms: the top two applicants together account for the overwhelming majority of activity, and all remaining named filers hold a single patent record each.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | University Health Network | 5 | |
| 2 | Pacesetter Inc | 4 | |
| 3 | Intermedics Inc | 1 | |
| 4 | Scharf | 1 | |
| 5 | Scharf Christoph Dr | 1 | |
| 6 | Telectronics Pacing Systems Inc | 1 |
This concentration implies that new entrants face a evidence snapshot where foundational testing methodologies are already staked out by a small group; however, the low absolute volume also means that a focused filing programme could achieve meaningful relative standing relatively quickly.
The most recent filing years should be treated as under-counted due to standard patent publication lag; the apparent absence of activity from 2021 onward does not necessarily reflect a complete halt in R&D. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
A 2020 activity spike dominates an otherwise sparse filing record
Annual filing data and technology classification together reveal a field that has never sustained high annual volume, with a single visible pulse in 2020 and a technology mix anchored almost entirely in electrotherapy.
Annual filing trend
All recorded filing activity is concentrated in 2020; no filings are recorded in any other year of the observed window. The recent years from approximately 2022 onward should be read as potentially under-counted due to publication lag rather than confirmed zero activity.
↗ Hover for values · click a bar to ask EurekaTechnology composition
The visible IPC branch is A61N (Electrotherapy and radiation therapy), which accounts for the large majority of patent records. A61B (Diagnosis and surgery) appears as a secondary branch, reflecting the diagnostic and measurement functions inherent in pacemaker testing workflows.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Cardiac pacemaker with loss of atrial capture mode…
An apparatus and method for treatment of pacemaker mediated tachycardia. A pacemaker detects serially recurring pacemaker mediated tachycardia and alters the mode of stimulation to a non-atrial pacing mode. The pacemaker also alters the mode of stimulation to a non-atrial pacing mode whenever atrial loss of capture is indicated, for example by failure to… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Method and apparatus for monitoring and displaying… | 304 |
| 2 | Apparatus and method for detecting the progression… | 166 |
| 3 | Control of pacing rate in dual-chamber, rate-adapt… | 57 |
| 4 | Combined programming wand and PSA for pacemaker an… | 25 |
| 5 | Electrotherapy device | 9 |
| 6 | Cardiac pacemaker with loss of atrial capture mode… | 6 |
| 7 | Apparatus and method for detecting progression of … | 5 |
| 8 | Intelligent vector electrode for a pacemaker or an… | 1 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
Assignee snapshot from the current evidence set
The applicants below are visible in this query result. Because the evidence set is relatively small, read this section as a directional snapshot rather than a full competitive ranking.
University Health Network
University Health Network holds 5 patent records, the highest count in this corpus. Its technology emphasis spans both A61N 1 (Electrotherapy and radiation therapy, 5 records) and A61B 5 (Diagnosis and surgery, 4 records), reflecting a broader testing methodology covering both stimulation delivery and diagnostic measurement. No applicant momentum data is available for trajectory assessment.
patent records: 5Pacesetter Inc
Pacesetter Inc holds 4 patent records, placing it second in the ranking. Its focus is concentrated entirely in A61N 1 (Electrotherapy and radiation therapy), with no recorded activity in adjacent diagnostic branches. No momentum data is available to assess whether its position is growing or stable relative to recent periods.
patent records: 4Frequently asked questions
The corpus comprises 5 patent families in scope. This is a small dataset, and the analysis reflects the full extent of evidence available within the defined search parameters.
University Health Network is the leading filer with 5 patent records, followed by Pacesetter Inc with 4 patent records. Together they account for the large majority of activity in this corpus.
The field is assessed as being in a Decline stage. Annual filing volume eased back from a peak in 2020, and no filings are recorded in subsequent years — though recent years may be under-counted due to publication lag.
A61N (Electrotherapy and radiation therapy) is the visible class, appearing in 14 patent records. A61B (Diagnosis and surgery) is a secondary class with 4 patent records.
The United States leads with 7 patent records, followed by Europe via the EPO with 5, Canada with 1, and WIPO PCT with 1. Coverage outside North America and Europe is not evidenced in this corpus.
No co-applicant collaboration relationships are identified in this corpus. The absence of recorded co-filing may reflect the small dataset size or the proprietary nature of testing methodology development in this area.
Built on Patsnap Open Platform
This report’s underlying patent dataset — filings, assignees, technology clusters — is open for developers via MCP and REST API. Free to start, 10,000 credits, no credit card required.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.